Clinicians who treat @entity308 are faced with a bewildering choice of antidepressants. Given that all have a lag period before they are effective, choice of the right antidepressant can potentially minimize the duration of symptoms, reduce cost and enhance compliance. Unfortunately, there is very little evidence upon which to base such a decision. We developed a treatment algorithm for non-psychotic, @entity308 , and applied it in our clinic. It includes progression from a specific @entity750 reuptake inhibitor (SSRI), usually @entity905 , from a dose of 20 mg to a dose of 40 mg in @entity1 who do not respond. Non-responders to this dose receive augmentation with @entity1954 (T3, 25-50 microg). All interventions are for fixed time periods and guided by overall clinical improvement as defined by the Clinical Global Inventory. Ninety @entity1 commenced open-label treatment with 20 mg SSRI ( @entity905 , n=81; @entity903 , n=9). Seventy-four @entity1 completed 4 wk of treatment and 44 (48.9%) were responders (intent to treat analysis). Raising the SSRI dose to 40 mg for a further 2 wk was effective in only 5 @entity1 (16.6%). Non-responders to SSRI were significantly more @entity308 at baseline as reflected by their rating scales scores. Addition of T3 was effective in 10 out of 16 @entity1 (62.5%) while none of the 9 males responded. Although values were within the normal range, @entity1 who responded to T3 had higher serum thyroid-stimulating hormone levels than those who did not. Our experience with algorithm-based treatment of unipolar, non-psychotic @entity308 in outpatients suggests that more than 40% of @entity1 will not respond to initial treatment with an SSRI even when the dose is increased to 40 mg/d; that severity of @entity308 may be an important predictor of response and that T3 may be useful as an augmenter of response in SSRI non-responders but may be less effective in @entity1 than in @entity1 . The effect of T3 may be related to thyroid function even within the normal range.

Algorithm-based treatment of XXXX in an outpatient clinic: clinical correlates of response to a specific @entity750 reuptake inhibitor and to @entity1954 augmentation.

@entity1 :: ('9606', 'Species') :: ['men', 'women', 'patients'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depressed', 'depression', 'major depression', 'unipolar major depression'] @entity905 :: ('MESH:D005473', 'Chemical') :: ['fluoxetine'] @entity903 :: ('MESH:D017374', 'Chemical') :: ['paroxetine'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin'] @entity1954 :: ('MESH:D014284', 'Chemical') :: ['triiodothyronine']
@entity308 :: (MESH:D003866,Disease) :: ['major depression']
